Buy Melanotan I 10mg

Melanotan I, now designated by the INN name afamelanotide, is a synthetic linear analog of α-melanocyte-stimulating hormone (α-MSH) with a single amino acid substitution — replacement of phenylalanine at position 7 with norvaline and an alpha-helical stabilizing modification — that confers dramatically increased metabolic stability compared to the native hormone while retaining selective high-affinity binding to the melanocortin-1 receptor (MC1R). This MC1R selectivity is the defining pharmacological property that distinguishes afamelanotide from Melanotan II: by engaging MC1R without significant affinity for MC3R or MC4R, afamelanotide produces eumelanin synthesis in melanocytes without triggering the central hypothalamic sexual arousal and appetite suppression pathways that cause MT-II's signature side effects. The MC1R signaling cascade activated by afamelanotide proceeds through Gαs-coupled cAMP elevation, PKA activation, and transcription factor MITF induction — identical to the signaling mechanism of α-MSH itself. MITF is the master regulator of the melanogenic gene program, directly driving expression of tyrosinase (the rate-limiting enzyme in melanin synthesis), tyrosinase-related protein 1 (TRP-1), and dopachrome tautomerase (TRP-2). Together these enzymes convert L-tyrosine to L-DOPA to dopaquinone and through several oxidative coupling steps to eumelanin, the high-molecular-weight photoprotective polymer. Eumelanin is physically located in melanosomes, which are transferred from melanocytes to adjacent keratinocytes and distributed as a supranuclear cap that shields the underlying DNA from UV photodamage. The photoprotective mechanism extends beyond simple UV absorption. Eumelanin produced by MC1R activation has been shown to improve the fidelity of UV-induced DNA damage repair by maintaining the availability of nucleotide excision repair (NER) enzymes in keratinocytes. Additionally, MC1R signaling activates BRCA1-dependent DNA damage recognition pathways, improving the cell's ability to detect and repair cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts — the two major classes of UV-induced mutagenic lesions. This dual UV-absorption plus DNA-repair-enhancement mechanism explains why MC1R-variant individuals (who have impaired MC1R signaling and consequently produce phaeomelanin instead of eumelanin) have dramatically elevated skin cancer risk disproportionate to their tanning impairment alone. Afamelanotide's sustained-release implant formulation (Scenesse, 16 mg subcutaneous biodegradable polylactic acid implant) provides approximately 2 months of continuous melanocortin stimulation from a single administration, obviating the need for repeated injections. The implant releases afamelanotide at a controlled rate that maintains blood concentrations in the range of 0.1–1 ng/mL — well below the concentrations associated with systemic melanocortin side effects while providing sufficient local and peripheral melanocyte stimulation for meaningful photoprotection. This delivery innovation was critical for the clinical viability of afamelanotide in EPP, where protection must be sustained continuously during spring and summer months.

The existence of FDA/EMA-approved Scenesse (afamelanotide 16 mg biodegradable implant) provides a quality reference benchmark for Melanotan I that is unique among research peptides. Research-grade Melanotan I in lyophilized powder form must contain the same amino acid sequence with identical modifications confirmed by mass spectrometry. The MW is 1646.9 g/mol for the complete 13-residue analog; HPLC purity ≥98% is standard. Unlike MT-II, Melanotan I is a linear (non-cyclic) peptide, so confirmation of correct sequence without cyclization artifacts is important. Research use protocols typically employ 0.5–1 mg subcutaneously every 2–3 days for a loading phase of 2–4 weeks to establish melanin production, followed by maintenance injections every 7–14 days to sustain the effect. This is considerably gentler than MT-II protocols given the absent MC4R effects that make MT-II dosing more aggressive. The absence of the nausea, spontaneous erection, and appetite suppression side effects means Melanotan I can be administered without prophylactic antiemetics and with less need for dose titration in most individuals. Dermatological baseline assessment — particularly documentation of existing nevi with photographs — is a reasonable precaution before initiating Melanotan I. Any mole that changes in appearance, size, or color during treatment should be evaluated promptly by a dermatologist. In individuals with prior skin cancer history, the risk-benefit calculation for a cosmetic tanning application does not favor use, though the therapeutic use in EPP represents a case where benefit clearly outweighs this theoretical concern.

The comparison between Melanotan I and Melanotan II for tanning applications favors Melanotan I unambiguously for individuals whose primary goal is photoprotection or cosmetic pigmentation. The identical MC1R mechanism means tanning efficacy is comparable on a dose-adjusted basis, but the complete absence of MC4R-mediated side effects (no spontaneous erections, no nausea at standard doses, no appetite suppression, no blood pressure effects) makes Melanotan I far more manageable. The availability of an FDA-approved formulation also means that the underlying science has undergone regulatory scrutiny, providing confidence in the therapeutic rationale. Against conventional sunscreens and sun-avoidance strategies, afamelanotide provides an active photoprotective mechanism — building intrinsic UV-absorbing capacity in the skin — rather than passive blocking. For individuals with conditions like EPP where UV exposure is unavoidable or whose quality of life is severely impacted by sun sensitivity, this active approach has demonstrated clinical superiority to topical protection alone. For recreational tanning purposes without a medical indication, weighing the nevi-darkening concern against the benefits of any melanocortin agonist is the key risk-benefit calculation, and Melanotan I's clinical approval status provides more reassurance than MT-II's entirely unapproved status.